Eli Lilly and Company $LLY Stock Holdings Reduced by Essex Savings Bank

Key Points

• Essex Savings Bank reduced its stake in Eli Lilly and Company by 4.2% in the second quarter, now holding 11,559 shares valued at approximately $9 million, making it the bank's 8th largest position.
• Insider transactions included CEO David A. Ricks purchasing 1,632 shares at over $1 million, indicating confidence in the company’s future performance.
• Eli Lilly reported a quarterly EPS of $6.31, surpassing estimates by $0.72, and has projected FY 2025 EPS guidance between $21.750 and $23.000.

Essex Savings Bank cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,559 shares of the company's stock after selling 502 shares during the period. Eli Lilly and Company accounts for approximately 2.1% of Essex Savings Bank's investment portfolio, making the stock its 8th biggest holding. Essex Savings Bank's holdings in Eli Lilly and Company were worth $9,011,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after acquiring an additional 31 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $9.41 on Friday, hitting $753.52. 7,319,147 shares of the company's stock were exchanged, compared to its average volume of 3,181,974. The firm's 50-day moving average price is $738.37 and its two-hundred day moving average price is $770.79. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market cap of $713.18 billion, a price-to-earnings ratio of 49.25, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company posted $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LLY. Berenberg Bank reiterated a "hold" rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday. Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. HSBC upgraded shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.